Similar to the mechanism we reported previously for the SPTLC1 ALS variants,5 we predict that this overproduction of sphingolipids in the E260K SPTLC2 variant is secondary to an impaired inhibitory effect of ORMDLs on the SPT complex. Here, AGXT is linked to amyotrophic lateral sclerosis.